Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
643
-
Total 13F shares, excl. options
-
132M
-
Shares change
-
+5.11M
-
Total reported value, excl. options
-
$43B
-
Value change
-
+$1.72B
-
Put/Call ratio
-
1.1
-
Number of buys
-
354
-
Number of sells
-
-271
-
Price
-
$326.09
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2025
766 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2025.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 643 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 132M shares
.
Largest 10 shareholders include Capital World Investors (16.8M shares), FMR LLC (15.8M shares), VANGUARD GROUP INC (13.3M shares), BlackRock, Inc. (9.98M shares), Capital Research Global Investors (7.19M shares), REGENERON PHARMACEUTICALS, INC. (4.44M shares), T. Rowe Price Investment Management, Inc. (4.28M shares), Dodge & Cox (3.2M shares), STATE STREET CORP (3.17M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (3.15M shares).
This table shows the top 643 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.